November 2020

FDA Approves Pralsetinib for Metastatic RET Fusion-Positive NSCLC
On September 4, 2020, the FDA approved Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) detected by an FDA-approved test. This indication was approved under the FDA’s Accelerated Approval program based on data from the phase I/II ARROW study. Read more.

Advertisement

Some Common Drugs May Reduce Lung Cancer Mortality
According to results from a population-based cohort study published in the Journal of Thoracic Oncology, combined usage of aspirin, statins, and metformin may be correlated with decreases in lung cancer incidence and mortality. Previous studies have demonstrated varied results on whether aspirin, metformin, or statins have a protective effect against cancers. Read more.

Lorlatinib Effective for Advanced Anaplastic Lymphoma Kinase–Positive NSCLC
Promising interim results from the randomized phase III CROWN study presented at the ESMO Virtual Congress 2020 for lorlatinib indicate that this agent considerably increased progression-free survival compared with crizotinib, validating the outcomes benefit of lorlatinib already seen in later-line ALK-positive nonsmall-cell lung cancer (NSCLC) settings (LBA2). Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App
Advertisement